| 摘要 |
<p><P>PROBLEM TO BE SOLVED: To provide a formulation for oral administration, having such a mizolastine-releasing profile as bringing about a lower peak in plasma without reducing bioavailability. <P>SOLUTION: A sustained-release pharmaceutical formulation containing mizolastine, a core formed of a sustained-release tablet containing mizolastine combined with a lipid matrix and an organic acid, the tablet being coated is provided. <P>COPYRIGHT: (C)2007,JPO&INPIT</p> |
